Skip to content
Doctors reviewing medical schedule

Elios Vision’s excimer laser trabeculostomy procedure receives new CPT codes from American Medical Association

Elios Vision, Inc. today announced that the ELIOS excimer laser trabeculostomy (ELT) procedure has received two new CPT codes from the American Medical Association. The two new codes, to be used for reporting trabeculostomy ab interno by laser with or without the use of an ophthalmic endoscope, are effective January 1, 2021.

The company’s ELIOS ELT device is a specialized excimer laser system used for microinvasive glaucoma surgery (MIGS) to lower eye pressure in patients with glaucoma. The product has already received a CE mark in Europe, where ELT has been the subject of numerous scientific publications. Review of published clinical studies using a new technology is a critical factor in the approval process of a CPT application. Preparations are underway to begin clinical trials of the device in the United States and to expand its international use.

The CPT system is a set of standardized codes to communicate nationwide medical procedures and services across health care systems and professionals, including health insurance companies, physicians, hospital facilities and laboratories. The issuance of a Category III code, a temporary code to describe emerging technologies, services and procedures, is an essential step toward a future permanent Category I code, used for widespread reimbursement of procedures performed in medical practices.

Kevin J. Corcoran, COE, CPC, CPMA, FNAO, President of Corcoran Consulting Group, assisted the company with the preparation of the CPT Code Change Application and also answered questions from the AMA’s CPT Panel during the February 2020 meeting which led to the approval of the two new CPT codes.

“A lot of effort is required for any CPT Code Change Application, and its success is largely dependent on the thoroughness of the preparation and fastidious presentation of the supporting information for the new procedure,” said Mr. Corcoran. Before submission, the application was vetted with the American Academy of Ophthalmology and gained their support.

“Multiple clinical studies across Europe have demonstrated that ELIOS ELT has a strong efficacy and safety profile, with significant advantages over other forms of microinvasive glaucoma surgery (MIGS),” said Elliot Friedman, Chief Executive Officer of ELIOS Vision. “Obtaining two CPT codes from AMA is an important milestone for ELIOS Vision and a critical step in positioning the company to become a leader in the surgical treatment of glaucoma.”

Share This Story

Latest News

Elios Vision announces collaboration with the International Glaucoma Surgical Registry

Elios Vision will be collaborating with the ISGR, an open-access tool which enables surgeons to compare outcomes with other centres.
Elios Vision logo

Elios Vision achieves three new pipeline milestones

Elios announced enrollment completion in their U.S. pivotal trial, the expansion of the U.S. pre-launch team, and continued commercial uptake in Europe.
The Ophthalmologist logo

The ELegance of ELIOS

Learn why Dusseldorf-based surgeon Karsten Klabe prefers the ELIOS procedure when treating patients for open-angle glaucoma.

Join Our Email List

Stay up-to-date on the next generation of glaucoma treatment. Subscribe to receive educational and promotional information from Elios Vision.

Email Signup

Site for Healthcare Professionals Only

You are about to access Elios Vision’s online platform for healthcare professionals outside of the United States. This platform is intended to provide general product information for education and illustration purposes. It is not intended to provide information to the general public or medical advice.

As product information, availability, indication, and trade names may vary from country to country, the content of this site may not be fully in-line with the approved or cleared product information in the country you are accessing from. Unless stated otherwise for specific product or event pages, the content on this site is based on the regulatory and legal principles applicable to the United Kingdom.

By clicking “Proceed,” I confirm that:

  • I understand that this platform is directed to Healthcare Professionals only and that I am a licensed Healthcare Professional.
  • I have read and agree to Elios Vision’s terms and conditions and privacy policy.